Market Analysis Report Insulin Pump Market | Page 2

Your Catalyst to a Lucrative Business market. Moreover, ongoing research projects related to implantation of insulin producing stem cell can hinder market growth in coming years. Technological developments, including home infusion therapy and artificial pancreas are likely to create lucrative growth opportunities for the market. Browse Details of Report @ https://www.hexaresearch.com/research-report/insulin-pump-market The market can be segmented on the basis of pump type, accessories, and end-users. Based on pump type, the market can be categorized into smart, disposable, and traditional. In terms of accessories, the market can be classified into insulin reservoirs, infusion sets, and infusion set insertion devices. On the basis of end-users, the market can be divided into home care, hospitals, clinics, and laboratories. North America is expected to grow fast in coming years attributed to increasing number of diabetic patients in the United States. Growing adoption of insulin pumps in the U.S. and Canada can drive the market in the region. According to a report by Centers for Disease Control and Prevention (CDC), one in three individuals in the U.S. is expected to have diabetes by 2050. Technological developments in medical devices can impel market growth in the region. In addition, launch of advanced infusion pumps by local manufacturing companies can augment growth of market in coming years. For instance, Medtronic launched Guardian Connect CGM system for people with diabetes. This system can alert patients of potential low or high of glucose events up to 60 minutes in advance. Guardian Sensor 3 used in this system is the most advanced glucose sensor made by the company. People using this system can also have access to Sugar.IQ smart diabetes assistant to address common problems related to diabetes. Similarly, Tandem Diabetes Care received approval from the U.S. Food and Drug Administration (FDA) for its slim X2 insulin pump with Basal-IQ technology. Basal-IQ predictive low glucose suspend (PLGS) feature is designed to lessen the duration and frequency of low glucose events. Asia Pacific is anticipated to witness significant growth in the coming years owing to increasing cases of diabetes in developing countries, such as India, China, and Japan. These countries are expected to contribute to more than 70 percent of the world’s diabetic population. China is estimated to hold the largest share in the market owing to presence of leading market players. For instance, Medtronic announced that it is planning to open its new operation site in China to address the increasing diabetes epidemic in the country. Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/medical-devices- industry Follow Us: